The predictive role of albumin, neutrophil-to-lymphocyte ratio, and systemic immune inflammation index in pressure ulcer risk among palliative care patients- a retrospective analysis.
{"title":"The predictive role of albumin, neutrophil-to-lymphocyte ratio, and systemic immune inflammation index in pressure ulcer risk among palliative care patients- a retrospective analysis.","authors":"Gozde Cingiz, Berkay Temel","doi":"10.1080/17520363.2026.2641466","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pressure ulcers (PUs) are a major concern in palliative care due to patients' immobility and multiple comorbidities. Early identification of at-risk individuals is essential for prevention. Hematological markers such as neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) may assist in risk prediction. Objectives: This study aimed to evaluate the predictive value of inflammatory markers for PU development in palliative care patients retrospectively.</p><p><strong>Methods: </strong>Adult patients hospitalized in a palliative care unit for at least three months and free of PUs at admission were included. They were categorized into two groups: those who developed PUs during follow-up (wPU) and those who did not (woPU). Demographic, clinical, and laboratory variables were compared.</p><p><strong>Results: </strong>A total of 82 patients (mean age: 78.6 ± 11 years) were analyzed. No significant differences were found between groups in terms of age, sex, Charlson Comorbidity Index, or Braden score. The wPU group had significantly lower serum albumin (<i>p</i> = 0.004), and higher NLR (<i>p</i> = 0.04) and SII (<i>p</i> = 0.04) levels.</p><p><strong>Conclusion: </strong>Hypoalbuminemia and elevated NLR independently predict PU development in palliative care, highlighting the importance of nutritional and inflammatory status. Albumin, NLR, and SII had only moderate accuracy but may provide supportive value when combined with clinical risk tools.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"207-212"},"PeriodicalIF":2.1000,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13007392/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2026.2641466","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/5 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Pressure ulcers (PUs) are a major concern in palliative care due to patients' immobility and multiple comorbidities. Early identification of at-risk individuals is essential for prevention. Hematological markers such as neutrophil-to-lymphocyte ratio (NLR) and systemic immune-inflammation index (SII) may assist in risk prediction. Objectives: This study aimed to evaluate the predictive value of inflammatory markers for PU development in palliative care patients retrospectively.
Methods: Adult patients hospitalized in a palliative care unit for at least three months and free of PUs at admission were included. They were categorized into two groups: those who developed PUs during follow-up (wPU) and those who did not (woPU). Demographic, clinical, and laboratory variables were compared.
Results: A total of 82 patients (mean age: 78.6 ± 11 years) were analyzed. No significant differences were found between groups in terms of age, sex, Charlson Comorbidity Index, or Braden score. The wPU group had significantly lower serum albumin (p = 0.004), and higher NLR (p = 0.04) and SII (p = 0.04) levels.
Conclusion: Hypoalbuminemia and elevated NLR independently predict PU development in palliative care, highlighting the importance of nutritional and inflammatory status. Albumin, NLR, and SII had only moderate accuracy but may provide supportive value when combined with clinical risk tools.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
